BioMarin Pharmaceutical Inc. (BMRN)
Chart Events
Performance Outlook
| Previous Close | 77.73 |
| Open | 77.65 |
| Bid | 76.40 x 2200 |
| Ask | 78.80 x 800 |
| Day's Range | 76.41 - 77.56 |
| 52 Week Range | 71.59 - 94.20 |
| Volume | |
| Avg. Volume | 1,305,810 |
| Market Cap | 14.113B |
| Beta (5Y Monthly) | 0.49 |
| PE Ratio (TTM) | 2,135.28 |
| EPS (TTM) | 0.04 |
| Earnings Date | Apr 27, 2022 - May 02, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 115.89 |
- Simply Wall St.
BioMarin Pharmaceutical (NASDAQ:BMRN shareholders incur further losses as stock declines 4.9% this week, taking five-year losses to 14%
For many, the main point of investing is to generate higher returns than the overall market. But the main game is to...
- PR Newswire
BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Company hired two pharmaceutical industry leaders in their respective areas of expertise. Humaira Serajuddin was named Senior Vice President, Chief Marketing Officer and Erin Burkhart was named Group Vice President, Chief Accounting Officer, filling two key strategic roles supporting BioMarin's growth goals.
- PR Newswire
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced five platform presentations and one poster presentation on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the World Federation of Hemophilia (WFH) 2022 World Congress from May 8-11 in Montreal, Canada.
